Business Context and Reporting Period
Company: U.S. Physical Therapy, Inc. (USPH)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal Year Ended December 31, 2025
Business Overview: USPH operates two reportable segments: Physical Therapy Operations (outpatient clinics, home care, and management services) and Industrial Injury Prevention (IIP) Services. As of December 31, 2025, the Company owned or managed 780 clinics across 44 states. The Company continues to pursue growth through acquisitions and strategic hospital alliances.
Key Financial Metrics
| Metric | 2025 | 2024 | Variance |
|---|---|---|---|
| Net Revenue | $781.0 million | $671.3 million | +16.3% |
| Net Patient Revenue | $650.4 million | $560.6 million | +16.0% |
| Gross Profit | $149.7 million | $123.9 million | +20.8% |
| Gross Margin | 19.2% | 18.5% | +70 bps |
| Operating Income | $86.7 million | $63.0 million | +37.6% |
| Net Income (GAAP) | $58.0 million | $45.6 million | +27.2% |
| Net Income Attributable to USPH Shareholders | $39.6 million | $31.4 million | +26.0% |
| Diluted EPS (GAAP) | $1.42 | $1.84 | -22.8% |
| Adjusted EBITDA (Non-GAAP) | $95.0 million | $81.8 million | +16.2% |
| Operating Results (Non-GAAP) | $40.0 million | $36.9 million | +8.4% |
| Cash and Cash Equivalents | $35.6 million | $41.4 million | -14.0% |
| Total Debt Outstanding | $161.8 million | $151.6 million | +6.7% |
| Available Credit | $144.5 million | $164.0 million | -11.9% |
Note: GAAP EPS decreased despite higher net income due to a $24.5 million revaluation charge to retained earnings associated with redeemable non-controlling interests.
Material Changes vs. Prior Period
- Revenue Growth: Driven by organic growth (14.9% increase in patient visits) and acquisitions. Physical Therapy Operations revenue increased 16.0%, while IIP revenue increased 18.0%.
- Margin Expansion: Gross profit margin improved to 19.2% from 18.5%, aided by a decrease in clinic closure costs ($0.3 million in 2025 vs. $4.4 million in 2024) and a $6.2 million gain on the change in fair value of contingent earn-out consideration.
- Acquisitions: Completed multiple acquisitions in 2025, including a 50% interest in Metro (a management services organization) in October 2024 (fully consolidated in 2025 results) and several multi-clinic practices. Total cash used for acquisitions and non-controlling interest purchases was approximately $25.9 million in 2025.
- Shareholder Returns: The Company repurchased 81,322 shares for $5.6 million in Q4 2025. Quarterly dividends were maintained at $0.45 per share throughout 2025.
Guidance, Outlook, and Risks
Outlook and Recent Developments
- Dividend Increase: On February 24, 2026, the Board raised the quarterly dividend to $0.46 per share.
- Strategic Alliances: Announced 10-year strategic alliances with hospital systems in New York and other locations to integrate clinics into hospital networks, expected to be accretive to revenue and margins.
- Medicare Reimbursement: The 2025 Medicare Physician Fee Schedule (MPFS) resulted in a ~2.9% decrease in reimbursement. The 2026 MPFS is expected to increase reimbursement by approximately 1.75%.
- ERP Implementation: The Company is implementing a new enterprise resource planning system to enhance operational efficiency, incurring one-time costs of $1.5 million in 2025.
Key Risks and Contingencies
- Regulatory & Reimbursement: Significant exposure to changes in Medicare/Medicaid rules, reimbursement rates, and potential retroactive reductions. Compliance with fraud and abuse laws (Anti-Kickback, Stark Law) remains a critical risk.
- Redeemable Non-Controlling Interests (RNCI): The Company has significant RNCI ($293.3 million at year-end). Increases in the value of these interests reduce GAAP EPS and retained earnings, though they do not impact cash flow until redemption.
- Debt Covenants: Subject to financial covenants including a Consolidated Fixed Charge Coverage Ratio and Consolidated Leverage Ratio. The Company was in compliance as of December 31, 2025.
- Cybersecurity: Ongoing risk of data breaches affecting patient information (HIPAA/HITECH compliance).
Investor Verification Checklist
- EPS Discrepancy: Verify the impact of the $24.5 million RNCI revaluation on GAAP EPS ($1.42) versus Non-GAAP Operating Results per share ($2.63).
- Acquisition Integration: Assess the financial performance and integration status of the Metro acquisition and other 2025 add-ons.
- Medicare Exposure: Confirm the sensitivity of the 35.8% of revenue derived from Medicare/Medicaid to the projected 1.75% rate increase in 2026.
- Debt Capacity: Review the $144.5 million available credit and the impact of the $25 million share repurchase authorization on future liquidity.
- Contingent Consideration: Monitor the fair value of contingent earn-out liabilities ($12.3 million at year-end) and potential future cash outflows.